257 related articles for article (PubMed ID: 34972658)
1. Self-Reported Severity, Characteristics, and Functional Limitations of Chemotherapy-Induced Peripheral Neuropathy.
Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
Pain Manag Nurs; 2022 Aug; 23(4):532-540. PubMed ID: 34972658
[TBL] [Abstract][Full Text] [Related]
2. The Association of Chemotherapy-Induced Peripheral Neuropathy Symptoms and the Risk of Falling.
Kolb NA; Smith AG; Singleton JR; Beck SL; Stoddard GJ; Brown S; Mooney K
JAMA Neurol; 2016 Jul; 73(7):860-6. PubMed ID: 27183099
[TBL] [Abstract][Full Text] [Related]
3. Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors.
Knoerl R; Mazzola E; Mitchell SA; Hong F; Salehi E; McCleary N; Ligibel JA; Reyes K; Berry DL
J Patient Rep Outcomes; 2021 Sep; 5(1):101. PubMed ID: 34568984
[TBL] [Abstract][Full Text] [Related]
4. Painful and non-painful chemotherapy-induced peripheral neuropathy and quality of life in colorectal cancer survivors: results from the population-based PROFILES registry.
Bonhof CS; Trompetter HR; Vreugdenhil G; van de Poll-Franse LV; Mols F
Support Care Cancer; 2020 Dec; 28(12):5933-5941. PubMed ID: 32281032
[TBL] [Abstract][Full Text] [Related]
5. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study.
Knoerl R; Mazzola E; Hong F; Salehi E; McCleary N; Ligibel J; Reyes K; Berry DL
BMC Cancer; 2021 Mar; 21(1):236. PubMed ID: 33676431
[TBL] [Abstract][Full Text] [Related]
6. The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA.
Wolf SL; Barton DL; Qin R; Wos EJ; Sloan JA; Liu H; Aaronson NK; Satele DV; Mattar BI; Green NB; Loprinzi CL
Support Care Cancer; 2012 Mar; 20(3):625-32. PubMed ID: 21479990
[TBL] [Abstract][Full Text] [Related]
7. Exploring Patients' Understanding of Chemotherapy-Induced Peripheral Neuropathy.
Knoerl R; Berry DL; Meyerhardt J; Reyes K; Salehi E; Gewandter JS
J Cancer Educ; 2023 Jun; 38(3):906-912. PubMed ID: 35927535
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-associated neuropathy characteristics compared with those associated with other neurotoxic chemotherapy agents (Alliance A151724).
Albany C; Dockter T; Wolfe E; Le-Rademacher J; Wagner-Johnston N; Einhorn L; Lafky JM; Smith E; Pachman D; Staff N; Ma C; Loprinzi CL; Costello BA
Support Care Cancer; 2021 Feb; 29(2):833-840. PubMed ID: 32500206
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of mirogabalin for chemotherapy-induced peripheral neuropathy: a prospective single-arm trial (MiroCIP study).
Misawa S; Denda T; Kodama S; Suzuki T; Naito Y; Kogawa T; Takada M; Suichi T; Shiosakai K; Kuwabara S;
BMC Cancer; 2023 Nov; 23(1):1098. PubMed ID: 37951905
[TBL] [Abstract][Full Text] [Related]
10. Impact of Pain on Symptom Burden in Chemotherapy-Induced Peripheral Neurotoxicity.
Mahfouz FM; Li T; Timmins HC; Horvath LG; Harrison M; Grimison P; Marx G; Goldstein D; Park SB
J Natl Compr Canc Netw; 2024 Feb; 22(2):108-116. PubMed ID: 38364373
[TBL] [Abstract][Full Text] [Related]
11. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice.
Nyrop KA; Deal AM; Reeder-Hayes KE; Shachar SS; Reeve BB; Basch E; Choi SK; Lee JT; Wood WA; Anders CK; Carey LA; Dees EC; Jolly TA; Kimmick GG; Karuturi MS; Reinbolt RE; Speca JC; Muss HB
Cancer; 2019 Sep; 125(17):2945-2954. PubMed ID: 31090930
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy-induced peripheral neuropathy (CIPN) in breast cancer survivors: a comparison of patient-reported outcomes and quantitative sensory testing.
Zhi WI; Chen P; Kwon A; Chen C; Harte SE; Piulson L; Li S; Patil S; Mao JJ; Bao T
Breast Cancer Res Treat; 2019 Dec; 178(3):587-595. PubMed ID: 31456070
[TBL] [Abstract][Full Text] [Related]
14. Exploring the efficacy of an electronic symptom assessment and self-care intervention to preserve physical function in individuals receiving neurotoxic chemotherapy.
Knoerl R; Weller E; Halpenny B; Berry D
BMC Cancer; 2018 Dec; 18(1):1203. PubMed ID: 30514351
[TBL] [Abstract][Full Text] [Related]
15. Mapping chemotherapy-induced peripheral neuropathy phenotype and health-related quality of life in patients with cancer through exploratory analysis of multimodal assessment data.
Wang M; Molassiotis A
Support Care Cancer; 2022 May; 30(5):4007-4017. PubMed ID: 35059866
[TBL] [Abstract][Full Text] [Related]
16. Self-Guided Online Cognitive Behavioral Strategies for Chemotherapy-Induced Peripheral Neuropathy: A Multicenter, Pilot, Randomized, Wait-List Controlled Trial.
Knoerl R; Smith EML; Barton DL; Williams DA; Holden JE; Krauss JC; LaVasseur B
J Pain; 2018 Apr; 19(4):382-394. PubMed ID: 29229430
[TBL] [Abstract][Full Text] [Related]
17. Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial.
Kleckner IR; Kamen C; Gewandter JS; Mohile NA; Heckler CE; Culakova E; Fung C; Janelsins MC; Asare M; Lin PJ; Reddy PS; Giguere J; Berenberg J; Kesler SR; Mustian KM
Support Care Cancer; 2018 Apr; 26(4):1019-1028. PubMed ID: 29243164
[TBL] [Abstract][Full Text] [Related]
18. Long-term chemotherapy-induced peripheral neuropathy among breast cancer survivors: prevalence, risk factors, and fall risk.
Bao T; Basal C; Seluzicki C; Li SQ; Seidman AD; Mao JJ
Breast Cancer Res Treat; 2016 Sep; 159(2):327-33. PubMed ID: 27510185
[TBL] [Abstract][Full Text] [Related]
19. Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment.
Zanville NR; Nudelman KN; Smith DJ; Von Ah D; McDonald BC; Champion VL; Saykin AJ
Support Care Cancer; 2016 Nov; 24(11):4779-89. PubMed ID: 27470258
[TBL] [Abstract][Full Text] [Related]
20. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches.
Knoerl R; Smith EML; Han A; Doe A; Scott K; Berry DL
Patient Educ Couns; 2019 Sep; 102(9):1636-1643. PubMed ID: 31003878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]